Open an account

Neuraxis

NRXS · NYSE American

$7.82−$0.03 (−0.38%)TodayMarket closed ·
Prev close $7.85

About NRXS

NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 24 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.

Employees
24
Headquarters
Carmel, Indiana
Listed
Aug 9, 2023
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
neuraxis.com

NRXS key statistics

Market cap
98.20M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
156.81K
Volume
57.88K
Open price
$7.86
High today
$8.00
Low today
$7.75
52 Week high
$9.33
52 Week low
$2.21

Neuraxis (NRXS) at a glance

Neuraxis (NRXS) last traded at $7.82, with a market cap of 98.20M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.75 and $8.00. The current price is 0.9% above the day's low and 2.2% below its high.

Volume so far is 57.88K shares, below the average of 156.81K shares a day.

Over the past year Neuraxis has ranged from $2.21 to $9.33, and now sits 79% of the way up that range.

Neuraxis met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.19 per share against an estimate of -$0.3264.

The average analyst price target is $11.22, 43.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $11.22
Low
$9.09
Now
$7.82
High
$13.65

NRXS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 23.8% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of $0.00
  2. Q4 FY24: reported -$0.21 per share against an estimate of $0.0408
  3. Q1 FY25: reported -$0.33 per share against an estimate of -$0.2448
  4. Q2 FY25: reported -$0.22 per share against an estimate of -$0.2091
  5. Q3 FY25: reported -$0.24 per share against an estimate of -$0.1734
  6. Q4 FY25: reported -$0.17 per share against an estimate of -$0.2193
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.1938
  8. Q2 FY26: reported -$0.19 per share against an estimate of -$0.3264

NRXS news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Neuraxis Reports Q1 2026 Results: Full Earnings Call Transcript

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Neuraxis Earnings Preview

  • Earnings Outlook For Neuraxis

  • Avi Kapoor

    Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings

Similar companies

Companies in the same industry as Neuraxis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.